{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:37:20Z","timestamp":1790537840749,"version":"4.1.0"},"reference-count":18,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Neurodegenerative diseases such as Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and Huntington\u2019s disease (HD), severely impact the function of neuronal cells in the brain and have devastating consequences on the quality of life of patients and their families [...]<\/jats:p>","DOI":"10.3390\/brainsci10090633","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T09:05:16Z","timestamp":1599815116000},"page":"633","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recent Advances and Future Perspectives in the Development of Therapeutic Approaches for Neurodegenerative Diseases"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3579-6403","authenticated-orcid":false,"given":"Melissa","family":"Bowerman","sequence":"first","affiliation":[{"name":"School of Medicine, Keele University, Staffordshire ST5 5BG, UK"},{"name":"Wolfson Centre for Inherited Neuromuscular Disease, RJAH Orthopaedic Hospital, Oswestry SY10 7AG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2165\/00002512-200623090-00001","article-title":"A review of the health-related quality of life and economic impact of Parkinson\u2019s disease","volume":"23","author":"Dowding","year":"2006","journal-title":"Drugs Aging"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Barbe, C., Jolly, D., Morrone, I., Wolak-Thierry, A., Dram\u00e9, M., Novella, J.-L., and Mahmoudi, R. (2018). Factors associated with quality of life in patients with Alzheimer\u2019s disease. BMC Geriatr., 18.","DOI":"10.1186\/s12877-018-0855-7"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/mds.27317","article-title":"Quality of Life in Huntington\u2019s Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life","volume":"33","author":"Mestre","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hussain, R., Zubair, H., Pursell, S., and Shahab, M. (2018). Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. Brain Sci., 8.","DOI":"10.3390\/brainsci8090177"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yiannopoulou, K.G., and Papageorgiou, S.G. (2020). Current and Future Treatments in Alzheimer Disease: An Update. J. Cent. Nerv. Syst. Dis., 12.","DOI":"10.1177\/1179573520907397"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and Treatment of Parkinson Disease: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kumar, A., Kumar, V., Singh, K., Kumar, S., Kim, Y.-S., Lee, Y.-M., and Kim, J.-J. (2020). Therapeutic Advances for Huntington\u2019s Disease. Brain Sci., 10.","DOI":"10.3390\/brainsci10010043"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.50.6_Suppl_6.S2","article-title":"History of levodopa and dopamine agonists in Parkinson\u2019s disease treatment","volume":"50","author":"Tolosa","year":"1998","journal-title":"Neurology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","article-title":"A resurrection of aducanumab for Alzheimer\u2019s disease","volume":"19","author":"Schneider","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin Expression in Patients with Huntington\u2019s Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mds.26082","article-title":"Levodopa therapy for Parkinson\u2019s disease: Pharmacokinetics and pharmacodynamics","volume":"30","author":"LeWitt","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson\u2019s disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Roberts, T.C., Langer, R., and Wood, M.J.A. (2020). Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov., 1\u201322.","DOI":"10.1038\/s41573-020-0075-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.tips.2019.06.003","article-title":"Insights into Computational Drug Repurposing for Neurodegenerative Disease","volume":"40","author":"Paranjpe","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/jnnp-2017-316988","article-title":"Convergent molecular defects underpin diverse neurodegenerative diseases","volume":"89","author":"Tofaris","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1096\/fj.201802592","article-title":"Modern approaches to investigating non-neuronal aspects of Alzheimer\u2019s disease","volume":"33","author":"Liddelow","year":"2019","journal-title":"FASEB J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JHD-130082","article-title":"Huntingtin: Here, there, everywhere!","volume":"2","author":"Humbert","year":"2013","journal-title":"J. Huntingt. Dis."},{"key":"ref_18","first-page":"231","article-title":"The Universal Non-Neuronal Nature of Parkinson\u2019s Disease: A Theory","volume":"5","author":"Valente","year":"2016","journal-title":"Cent. Asian J. Glob. Health"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/10\/9\/633\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:09:06Z","timestamp":1760177346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/10\/9\/633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["brainsci10090633"],"URL":"https:\/\/doi.org\/10.3390\/brainsci10090633","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,11]]}}}